Surgery Combined with Postoperative 125i Seed Brachytherapy for the Treatment of Mucoepidermoid Carcinoma of the Parotid Gland in Pediatric Patients

Ming-hui Mao,Lei Zheng,Xi-ming Wang,Hua Li,Li-zheng Qin,Jie Zhang,Zheng-xue Han,Jian-guo Zhang
DOI: https://doi.org/10.1002/pbc.26217
IF: 2.441
2016-01-01
Brachytherapy
Abstract:BackgroundThis retrospective study was undertaken to analyze the effectiveness and safety of surgery combined with postoperative I-125 seed brachytherapy in the treatment of mucoepidermoid carcinoma (MEC) of the parotid gland with risk factors in pediatric patients.ProcedureFrom September 2002 to January 2012, 24 patients, ages 5-16 years (mean, 13.2 years; median, 12.3 years), with MEC of the parotid gland were included. Patients with high risk factors received I-125 seed brachytherapy (median actuarial D90, 97 Gy) within 4 weeks following surgery. Radioactivity was 18.5-33.3 MBq per seed and the prescription dose was 60-120 Gy. Overall and disease-free survival rates, local control rate, and distant metastasis were recorded. Radiation-associated late side effects, including dermatitis, hearing loss, thyroid nodules, and secondary malignancy, were also evaluated.ResultsDuring the follow-up period of 5-13.4 years (median, 7.2 years), the overall and disease-free survival rates were all 100%. No patients developed local recurrence, regional/distant metastasis, and no severe radiation-associated complications including the second malignancy were noted.ConclusionSurgery combined with postoperative I-125 seed brachytherapy is effective and safe in the treatment of MEC of the parotid gland in pediatric patients, with no evidence of severe late radiation-related complications. More patients and longer follow-up data are still needed to prove the efficacy of I-125 brachytherapy.
What problem does this paper attempt to address?